Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple generative AI models and AlphaFold structures for drug discovery.
Medartis reports 13% revenue growth on Group level, driven by strong regional growth in the US (21%) and EMEA (18%) –improvement of EBITDA* margin to 17% – Biotech Investments
Medartis Holding AG / Key word(s): Half Year Results 20-Aug-2024 / 07:05 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The
August 21, 2024